Related Experiment Videos
Prognostic factors in malignant mesothelioma
Jacobus A Burgers1, Ronald A M Damhuis
1Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam. s.burgers@nki.nl
Lung Cancer (Amsterdam, Netherlands)
|July 21, 2004
Summary
Validated prognostic factors for malignant mesothelioma, such as performance status and histology, have limited clinical use but aid in study design. Further research is needed for biological factors to guide new therapies.
Area of Science:
- Oncology
- Mesothelioma Research
Background:
- Numerous prognostic factors exist for malignant mesothelioma.
- Few have been validated by prospective studies.
Purpose of the Study:
- To review the validated prognostic factors for malignant mesothelioma.
- To discuss their current clinical utility and future potential.
Main Methods:
- Literature review of validated prognostic factors.
- Analysis of their role in clinical practice and research.
Main Results:
- Validated factors include performance status, histology, weight loss, and leukocyte count.
- These factors have limited predictive value for patient survival in current practice.
- Their primary importance lies in defining patient cohorts for clinical studies.
Conclusions:
- Validated prognostic factors for malignant mesothelioma are limited in clinical application.
- Further prospective trials are required for biological prognostic factors.
- Future applications may include guiding new therapies and predicting tumor response.